Chalan et al., 2015 - Google Patents
Rheumatoid arthritis, immunosenescence and the hallmarks of agingChalan et al., 2015
View HTML- Document ID
- 15588280662819303590
- Author
- Chalan P
- van den Berg A
- Kroesen B
- Brouwer L
- Boots A
- Publication year
- Publication venue
- Current Aging Science
External Links
Snippet
Age is the most important risk factor for the development of infectious diseases, cancer and chronic inflammatory diseases including rheumatoid arthritis (RA). The very act of living causes damage to cells. A network of molecular, cellular and physiological maintenance …
- 206010039073 Rheumatoid arthritis 0 title abstract description 253
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
- C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Chalan et al. | Rheumatoid arthritis, immunosenescence and the hallmarks of aging | |
Trowbridge et al. | Innate immune pathways and inflammation in hematopoietic aging, clonal hematopoiesis, and MDS | |
Syrett et al. | Loss of Xist RNA from the inactive X during B cell development is restored in a dynamic YY1-dependent two-step process in activated B cells | |
Webb et al. | Protein arginine methyltransferase 5 promotes cholesterol biosynthesis–mediated Th17 responses and autoimmunity | |
Sánchez-Abarca et al. | Immunomodulatory effect of 5-azacytidine (5-azaC): potential role in the transplantation setting | |
Yang et al. | Critical roles of mTOR Complex 1 and 2 for T follicular helper cell differentiation and germinal center responses | |
Torres et al. | Inherited BCL10 deficiency impairs hematopoietic and nonhematopoietic immunity | |
Coquery et al. | BAFF regulates follicular helper T cells and affects their accumulation and interferon‐γ production in autoimmunity | |
US20220016166A1 (en) | T-cell expressing chimeric receptor | |
JP2019518460A (en) | Manipulated Treg cells | |
JP2020524149A (en) | Regulatory T cells, regulatory B cells, and method of regulating immune response using modulator of APRIL-TACI interaction | |
CN110753755A (en) | T cell depletion state specific gene expression regulator and use thereof | |
Shi et al. | TSC1/mTOR-controlled metabolic–epigenetic cross talk underpins DC control of CD8+ T-cell homeostasis | |
Lee et al. | IFNγ signaling endows DCs with the capacity to control type I inflammation during parasitic infection through promoting T-bet+ regulatory T cells | |
Raugh et al. | Nature vs. nurture: FOXP3, genetics, and tissue environment shape Treg function | |
Zhdanov et al. | Contact-independent suppressive activity of regulatory T cells is associated with telomerase inhibition, telomere shortening and target lymphocyte apoptosis | |
JP2016529208A (en) | KIR3DL2 is a useful biomarker and therapeutic target to prevent and treat a subset of cutaneous and non-cutaneous peripheral T-cell lymphomas, respectively | |
Fraszczak et al. | The transcription factors GFI1 and GFI1B as modulators of the innate and acquired immune response | |
Lucca et al. | Co‐inhibitory blockade while preserving tolerance: checkpoint inhibitors for glioblastoma | |
EP3090751A1 (en) | Molecular profiling of cd8 t-cells in autochthonous melanoma identifies maf as driver of exhaustion | |
Crispín et al. | T cells | |
US20140288149A1 (en) | Mir-142 and antagonists thereof for treating disease | |
US12109266B2 (en) | Modulating gabarap to modulate immunogenic cell death | |
Brouwer et al. | Rheumatoid arthritis, immunosenescence and the hallmarks of aging | |
Kuksin | Elucidating Cellular Signaling Pathways that Contribute to the Immunopathogenesis of Aplastic Anemia |